Expert Ratings For Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) has been analyzed by 7 analysts, showing a mix of bullish to bearish sentiments. Recent adjustments in ratings and price targets reflect varying analyst expectations, with an average 12-month price target of $78.86, a decrease from the previous $83.20. The company, known for its medical devices for heart disease, shows strong financial performance with a notable revenue growth rate of 12.27% and high net margin of 25.99%, despite a lower growth rate compared to its peers.
February 02, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Edwards Lifesciences has seen varied analyst ratings and price target adjustments, indicating mixed market perceptions. Despite this, the company's strong financial performance, including a 12.27% revenue growth and a high net margin of 25.99%, positions it well in the market.
The mixed analyst ratings and recent adjustments in price targets reflect uncertainty and varied expectations among analysts, which could lead to short-term volatility in EW's stock price. However, the company's strong financial performance, particularly its revenue growth and net margin, may counterbalance the impact of mixed analyst sentiments, leading to a neutral short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100